Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624125 | 0.91 | USP30 (0.53) | GBA1PKMMEN1KMT2AHDAC1 | |
| SCHEMBL3274646 | 0.91 | USP30 (0.53) | GBA1PKMMEN1KMT2AHDAC1 | |
| SCHEMBL13738679 | 0.91 | USP30 (0.53) | GBA1PKMMEN1KMT2AHDAC1 | |
| Hydrochloric Acid SCHEMBL3272901 | 0.90 | USP30 (0.52) | GBA1PKMMEN1KMT2AHDAC1 | |
| SCHEMBL3372477 | 0.89 | HDAC1 (0.58) | PKMMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL3040088 | 0.87 | OPRM1 (0.52) | GBA1PKMMEN1KMT2AHDAC1 | |
| SCHEMBL5722085 | 0.86 | HDAC1 (0.53) | PKMMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL5722086 | 0.86 | HDAC1 (0.53) | PKMMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL8773484 | 0.84 | HDAC1 (0.61) | PKMMEN1KMT2AHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL22407358 | 0.84 | MEN1 (0.50) | GBA1PKMMEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3026049-B1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | DONG A ST CO LTD (KR) | 2021-09-22 | — | — | EP | disclosed |
| US-9771348-B2 | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate | DONG-A ST CO., LTD (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20160185751-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | DONG-A ST CO., LTD (KR) | 2016-06-30 | — | — | US | disclosed |
| EP-3026049-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | Dong-A ST Co., Ltd. (KR) | 2016-06-01 | — | — | EP | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776885-B2 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | GBA1 2585/4885PKM 4717/4885MEN1 4105/4885 |
| US-20160185751-A1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | HTR4, HTR5A, HTR2B | GBA1 1383/4885PKM 1910/4885MEN1 2555/4885 |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | GBA1 2584/4885PKM 3536/4885MEN1 4724/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | GBA1 536/4885PKM 2417/4885MEN1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.